Optimizing Early Clinical investigations in Cancer Immunotherapy – the Translational journey of RG6292, an IL-2 Signaling Preserving, Treg Depleting CD25 Antibody

Time: 4:00 pm
day: Day Two


  • Specifically depleting Tregs while preserving IL-2 signaling in an anti-CD25 antibody, currently being evaluated in Phase 1 trials for cancer
  • Integrating in vitro an din vivo PK/PD safety data from three species to identify
    human relevant safety risks, safe starting dose selection and pharmacologically relevant dosage
  • Validating the safety, PK and PD profiles from animal to man with clinical data